MRNA spotlight — 2026-10-06
MRNA saw a significant single-day increase of 6.95%, closing at $203.21 on Monday, October 5. This substantial move comes amidst a period of strong performance for the stock: over the past three months, MRNA has surged by 154.74%, and its…
Key figures
Data as of Oct 6, 2026- MRNA last close
- $203.21
- MRNA change vs prior close
- 6.95%
- MRNA market cap
- $80.68B
MRNA saw a significant single-day increase of 6.95%¹, closing at $203.21 on Monday, October 5². This substantial move comes amidst a period of strong performance for the stock: over the past three months, MRNA has surged by 154.74%³, and its market cap now stands at $80.68B⁴.
Despite this impressive growth, it's important to note that MRNA is not currently profitable; its latest reported EPS was -1.97⁵. This loss reframes the valuation of the company, as profitability has yet to materialize despite the recent surge in stock price.
MRNA’s current position is near its 52-week high at 96.9%⁶, and it currently trades well above both its 50-day average by 60.49%⁷ and its 200-day average by 193.43%⁸. The recent trading volume of 19,313,308 shares was also higher than the typical daily average at 1.33x⁹.
Recent news sentiment for MRNA has been mixed, with three positive articles and two negative ones out of six, suggesting ongoing interest and varied opinions about its future prospects.
Moderna, Inc. Common Stock (MRNA): price and news
Full chart and figuresDaily closes up to Oct 5, 2026, the last session before this was written.
News
- Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026Press releaseGlobeNewswire Inc.5d agoPositive
Inclusion in the Nasdaq-100 Index is a positive development as it indicates recognition of Moderna as one of the largest non-financial Nasdaq-listed companies and will likely increase institutional investment exposure through the 200+ investment products tracking the index.
- Moderna (MRNA) Stock Dips While Market Gains: Key FactsZacks Investment Research5d agoNegative
Moderna faces significant headwinds with projected year-over-year earnings decline of 166.67% and revenue decline of 12.52%. Full-year guidance shows negative earnings of -$8.5 per share. While the stock appreciated 27.69% over the past month, the company's deteriorating financial outlook and Hold rating indicate cautious investor sentiment.
- Prediction: Moderna Stock Will Soar 100% by 2030The Motley Fool6d agoPositive
Company showing strong turnaround with diversified product portfolio, positive phase 3 trial data for cancer vaccine candidate, cost realignment bearing fruit, recent 500% stock gain, and projected 10% revenue growth. However, analyst tempers expectations with cautious 100% prediction through 2030 due to high current valuation (P/S of 37) and manufacturing challenges ahead.
- Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?Zacks Investment Research6d agoPositive
Company has successfully expanded beyond COVID-19 with approved RSV and flu vaccines, demonstrated positive results with intismeran cancer therapy in melanoma, and is advancing nine additional oncology studies. Year-to-date stock performance up 590% and analyst estimates for bottom-line have improved over past 60 days.
- Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?The Motley FoolSep 28Negative
While the intismeran trial results are positive and represent a significant development, the author believes the stock is overvalued at current prices (~$200) compared to analyst consensus targets (~$77). The author warns there is too much optimism priced in and advises against buying at current valuations, despite acknowledging the drug's potential.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Educational tool. Not investment advice. This article was produced with automated assistance. Every figure in it was checked against the underlying data before it was published; the interpretation was not.